Achieve Life Sciences Stock News

SEATTLE and VANCOUVER, British Columbia, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV ), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it has initiated screening of ORCA-3, the confirmatory Phase 3 trial required for registrational approval of cytisinicline in the United States. ORCA-3 will evaluate the efficacy and safety of 3 mg cytisinicline dosed 3 times daily compared to placebo in 750 adult smokers at 15 clinical sites. Similar to the first registrational Phase 3 ORCA-2 trial, ORCA-3 participants will be randomized to one of three study arms to evaluate cytisinicline administered for either 6 or 12 weeks, compared to placebo. All subjects will receive standard behavioral support and will be assigned to one of the following groups: Arm A: 12 weeks of placebo Arm B: 6 weeks of cytisinicline, followed by 6 weeks of placebo Arm C: 12 weeks of cytisinicline The primary outcome measure of success in the ORCA-3 trial is biochemically verified continuous abstinence during the last four weeks of treatment in the 6 and 12-week cytisinicline treatment arms compared with placebo.

Achieve Life Sciences Inc (NASDAQ: ACHV) has initiated the screening in the ORCA-3 Phase 3 trial of cytisinicline for smoking cessation. The trial will evaluate the efficacy and safety of 3 mg cyti

SEATTLE, Wash, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV ), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that John Bencich, Chief Executive Officer, will give a presentation at the H.C. Wainwright BIOCONNECT Virtual Conference. The conference is taking place virtually from January 10 - 13, 2022. Details for access to the presentation are as follows: H.C. Wainwright BIOCONNECT Virtual Conference: Date: January 10, 2022 Time: 7:00 am ET Investors can register for the conference HERE . Following the conference, a webcast replay of the presentation will be available on Full story available on Benzinga.com

SEATTLE, Wash, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisi

SEATTLE and VANCOUVER, British Columbia, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV ), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it has entered into a $25 million debt agreement with Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P. ("SVB"). The proceeds and funds available under the debt agreement are expected to fund the completion of the cytisinicline smoking cessation clinical development program. As part of the contingent convertible debt agreement, SVB will fund $15 million in the form of convertible indebtedness to Achieve at closing on December 22, 2021. Subject to the terms and conditions of the debt agreement and upon Achieve''s and SVB''s mutual consent (including each Lender''s receipt of all necessary internal and credit approvals), Achieve may borrow additional non-convertible term loans in an aggregate original principal amount of up to $10 million. "We are pleased to have entered into a financing agreement with Silicon Valley Bank," said John Bencich, Chief Executive Officer of Achieve Life Sciences.

Achieve Life Sciences Inc (NASDAQ: ACHV) has entered into a $25 million debt agreement with Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P.  The proceeds and funds available under th

Geode Capital Management LLC grew its position in shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) by 93.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 56,669 shares of the biopharmaceutical companys stock after acquiring an additional 27,379 shares []

SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the Company will host a Key Opinion Leader (KOL) virtual panel event on smoking and e-cigarette cessation on Thursday, December 2nd, 2021, at 1:00 PM EST.

Following the fifth and final DSMC review, committee has concluded no concerns with cytisinicline safety or Phase 3 trial conduct Following the fifth and final DSMC review, committee has concluded no concerns with cytisinicline safety or Phase 3 trial conduct

SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development

The FDA has signed off Achieve Life Sciences Inc's (NASDAQ: ACHV) Investigational New Drug (IND) application to investigate cytisinicline as a cessation treatment for nicotine e-cigarette users. In

Seattle, WA/ Vancouver, BC , Oct. 26, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercializ

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / September 15, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commerciali

SEATTLE, WA & VANCOUVER, BC / ACCESSWIRE / September 14, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercializa

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 13, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercializat